natgillin/translations-raw huggingface dataset:
The expansion joint according to any one of claims 1 to 13, wherein the dividing members (4, 6) and the corrugated plates (5, 17) are formed of a substantially rigid material; in particular a metallic material; more in particular steel. 
Kompenzacijski spoj prema bilo kojem od zahtjeva 1 do 15, naznačen time da su razdjelni elementi (4, 6) gornjeg dijela 1 valovite ploče (15, 17) donjeg dijela oblikovani od u biti čvrstog materijala; posebno od metalnog materijala; posebno od čelika.
ND: not determined. *expression in rat glioma C6 cells. 
NO: nije određeno. ekspresija u štakorskim glioma C6 stanicama.
precipitating Factor H from the first supernatant, in a second precipitation step, with between about 20% and about 30% alcohol at a pH of between about 6.7 and about 7.3 to form a second precipitate; 
taloženje IgG iz sloja s površine s oko 20% do oko 30% alkohola na nižoj temperaturi i na pH-vrijednosti od oko 6,7 do oko 7,3, za tvorbu prvog taloga,
An apparatus for bonding the outer shell and inner cup to form an insulated container for hot liquids comprises such a first member to be arranged within the cup body, such second member generally concentric with said first member and arranged outside the outer shell, and at least one radially protruding or movable pressing member to press the opposed shell and cup walls together to form the bonding spots and/or bonding areas along the circumference of the shell and the cup body. 
Odgovarajući uređaj za spajanje vanjske ljuske i unutarnje čaše, koji omogućava izradu izoliranog spremnika za vruće tekućine ili nešto slično, ima takav prvi element koji treba biti postavljen s unutarnje strane čaše i takav drugi element koji je uglavnom koncentričan s prvim elementom i postavljen je s vanjske strane vanjske ljuske, i najmanje jedan radijalno izbočeni ili radijalno pomični tlačni element koji pritišće zajedno sa suprotnih strana ljusku i stijenke čaše, da
The amorphous solid dispersion for use according to Claim 4, wherein the therapeutic agent is selected from trastuzumab, capecitabine, bevacizumab, paclitaxel and docetaxel. 
Disperzija amorfne krutine, namijenjena upotrebi u skladu s patentnim zahtjevom 4, naznačena time što se terapijsko sredstvo bira između trastuzumaba, kapecitabina, bevacizumaba, paklitaksela i docetaksela.
The combined ether extract was dried (MgS04), filtered and evaporated under vacuum to an oil, which was crystallized by dissolution in hexane (100 ml.) followed by scratching the flask to initiate crystallization (48 g., 70% yield, m.p. 
Spojeni eterski ekstrakt se suši (MgSOy), filtrira 1 ispari u vakuumu do ulja, koje kristalizira otapanjem u heksanu (100 ml.) i zatim grebanjem balona da se inicira kristalizacija (48 g., 70% prinos, t.t. 98-99%C, elementarna analiza izrač.: 69.50% C; 5.22% H; 5.70% F; nađeno:
A pharmaceutical composition according to claim 5, wherein the composition is in the form of a tablet, a capsule, or a powder in vial or ampoule. 
Spoj za upotrebu prema zahtjevu 8, naznačen time što je spoj s formulom I osiguran u obliku hidrokloridne soli.
A compound of Formula (I) according to claim (I) selected from the group consisting of: 
Spoj formule (IT) prema patentnom zahtjevu 1 odabran iz skupine koju čine: HR P20180973 T1
resuspending the thus-precipitated collagen to a concentration of 1 to 30 mg/ mL in weakly acidic solvent or PBS, followed by storage at 4°C. 
resuspendiranja tako istaloženog kolagena na koncentraciju od 1 do 30 mg/ mL u slabo kiselom otapalu ili PBS, te potom pohranjivanja na 4°C.
System for treating water at low cost, according to claim 1, wherein the collecting line comprises a flexible hose, rigid hose, pipe, or a combination thereof. 
Uređaj za obradu vode uz nizak trošak, prema bilo kojem prethodnom zahtjevu, naznačen time što sabirni vod (15) sadrži savitljivo crijevo, kruto crijevo, cijev, ili njihovu kombinaciju.
reacting the 5-aceryl-8-hydroxy-(1H)-quinolin-2-one prepared in Step (a) with a compound having the formula R-Q in the presence of a base and a solvent to form 5-acetyl-8-substituted oxy-(1H)-quinolin-2-one, wherein R is a protecting group and Q is a leaving group; 
(b) reakciju 5-acetil-8-hidroksi-(1H)-kinolin-2-ona pripremljenog u koraku (a) sa spojem koji ima formulu R-Q u prisutnosti baze i otapala da bi se formirao 5-acetil-8-supstituiran oksi-(1H)-kinolin-2-on, gdje R je zaštitna skupina i Q je odlazeća skupina;
The process according to claim 11, wherein said co-catalyst is selected from organometallic compounds or mixtures of organometallic compounds of an element M' different from carbon, capable of reacting with the cobalt complex with at least one phosphine ligand selected from selected from hindered aliphatic phosphines or bidentate phosphines, according to claim 10, extracting therefrom a mono or polyvalent anion, to form on the one hand, at least one neutral compound, and on the other, an ionic compound consisting of a cation containing the metal (Co) coordinated by the ligand, and a non-coordinating organic anion containing the metal M', wherein the negative charge is delocalized on a multicentric structure, such as organic compounds of aluminium and especially boron, such as those represented by the following general formulae (V), (VI) or (VII): 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što se navedeni sukatalizator bira između organometalnih spojeva ili smjesa organometalnih spojeva elementa M' koji nije ugljik, koji može reagirati s kompleks kobalta s najmanje jednim fosfinskim ligandom, kojeg se bira između ometanih alifatskih fosfina ili bidentatnih fosfina, u skladu s patentnim zahtjevom 10, iz kojih se izvadi jedno- ili viševalentni anion, kako bi se dobilo, u jednu ruku, najmanje jedan neutralni spoj, a u drugu, ionski spoj, koji se sastoji od kationa koji sadrži metal (Co), koordiniran s ligandom, i nekoordinirajućeg organskog aniona, koji sadrži metal M', gdje je negativni naboj delokaliziran na višecentričnoj strukturi, poput organskih spojeva aluminija i osobito bora, poput onih koje predstavljaju sljedeće opće formule (V), (VT) ili (VID):
The method of claim 30, wherein at least about 90% of the amine residues on the lysines and the N-terminal amino acid of the erythropoietin are carbamylated. 
. Postupak prema patentnom zahtjevu 30, naznačen time što je najmanje oko 90% amino ostataka na lizinima i N- terminalnoj aminokiselini eritropoetina karbamilirano.
A developer supply container according to any one of Claims 1 - 6, wherein said drive converting portion (2d, 3b) converts the rotational force so that said pump portion (2b) reciprocates a plurality of times per one full rotation of said feeding portion (2c). 
Spremnik za nadopunjavanje razvijača u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što navedeni dio za pretvorbu pogona (2d, 3b) pretvara silu vrtnje na takav način da navedeni crpni dio (2b) mijenja djelovanje više puta po jednom punom okretu navedenog dijela za punjenje (2c).
In the apparatus of the invention, the annular end of sleeve 34 serves as an anvil member. 
U uređaju prema izumu anularni kraj košuljice 34 služi kao član nakovnja.
Process according to claim 41, wherein the caramelised feedstock contains at least 10%, preferably at least 30% caramel by weight of dry matter. 
Postupak prema zahtjevu 41, naznačen time, što karamelizirana sirovina sadržava najmanje 10%, poželjno najmanje 30% karamele, po masi suhe tvari.
wherein s is an integer equal to zero, 1, 2, 3 or 4; r is an integer equal to 1, 2, 3, 4 or 5; and R11 s hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R11 radicals may be taken together to form together with the phenyl ring to which they are attached a naphthyl; 
HR P20131116 TI pri čemu s je cijeli broj jednak nula, 1, 2, 3 ili 4; r je cijeli broj jednak I, 2, 3, 4ili 5; i R je vodik, halo, haloalkil, hidroksi, Ar, alkil, alkiloksi, alkiltio, alkiloksialkil, alkiltioalkil, Ar-alkil ili di(Ar)alkil; ili dva susjedna R'' radikala mogu biti uzeti da zajedno sa fenilnim prstenom na koji su spojeni tvore naftil;
40 contains representative images of crushed tablets. 
Primjer Z/: Reprezentativne slike zdrobijenih tableta
The thermally insulating stretchable sheet as claimed in claim 1, wherein said elastomeric binding strands are polymer strands having a softening point below 80 degrees C. 
Toplinski izolirajući rastezljivi sloj paperja (10) u skladu s patentnim zahtjevom 1, naznačen time što su navedena toplinski spojiva vezivna elastomerna vlakna (15?) niskomolekulski polimeri s točkom mekšanja ispod 80 *C.
A method of culturing heterologous protein-secreting mammalian cells in a cell culture supernatant wherein the cell culture supernatant is maintained at a temperature that is set at X±0.9°C, wherein X has a value of from 35.1 to 36.5, such as wherein the temperature is set at 36±0.9°C, 36±0.5°C, 36±0.2°C, 36 °C, 35.1±0.9°C, 35.1±0.5°C, 35.1±0.2°C, 35.1°C, 36.5±0.9°C, 36.5±0.5°C, 36.5±0.2°C or 36.5°C, with the proviso that the temperature is set at less than 37°C, wherein the culture is a continuous culture. 
Postupak uzgoja sisavačkih stanica koje izlučuju heterologni protein u supernatantu kulture stanica, naznačen time što supernatant kulture stanica ima koncentraciju otopljenog CO2 od 1 do 10%, gdje je kultura stanica kontinuirana kultura koju se održava uz gustoću od 1,4 × 106 do 2,8 × 106 stanica/ml.
The process according to any one of the preceding claims, wherein the medium further comprises amino acids selected from Alanine, Arginine, Aspartic Acid, Cysteine. Glutamic Acid, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenyalanine, Proline, Serine, Tryptophan, Tyrosine, Threonine, and Valine, but no Glutamine. 
Proces u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da medij nadalje sadrži aminokiseline odabrane između alanina, arginina, aspartatske kiseline, cisteina, glutaminske kiseline, glicina, histidina, izoleucina, leucina, lizina, metionina, fenilalanina, prolina, serina, triptofana, tirozina, treonina i valina, ali ne i glutamin.
The initiation of martensitic transformation of the population of zirconia particles by means of application of ultrasound can advantageously be combined with the curing of the resin base by means of ultrasound, see, e.g., under “Combined initiation of martensitic transformation and curing of resin base by means of ultrasound”. 
HR P20080380 T3 Inicijacija martenzitske transformacije populacije cirkonijeva oksida pomoću primjene ultrazvuka može pogodno biti kombinirana s očvršćivanjem baze za smolu pomoću ultrazvuka, vidi npr. pod "Kombinirana inicijacija martenzitske transformacije i očvršćivanja baze za smolu pomoću ultrazvuka",
is selected from N and CH; Z is selected from phenyl, pyrazinyl, pyridinyl, pyridazinyl and piperazinyl; wherein each phenyl, pyrazinyl, pyridinyl, pyridazinyl or piperazinyl of Z is optionally substituted with an R6 group; 
je odabran od N i CH, Z je odabran od sljedećih: fenil, piranizil, piridinil, piridazinil i piperazinil; pri čemu je svaki fenil, pirazinil, piridinil, piridazinil ili piperazinil od Z opcijski supstituiran s R6-skupinom;
The pharmaceutical composition according to any one of claims 1-2, wherein the sense strand comprises SEQ ID NO:98 and the antisense strand comprises SEQ ID NO:165; wherein the sense strand further comprises 2'-5'-ribonucleotides in positions 15, 16, 17, 18, and 19; a C3-OH 3' moiety covalently attached at the 3'-terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5'-terminus; and the antisense strand further comprises 2'-O-methyl modified ribonucleotides in positions 2, 4, 6, 8, 11, 13, 15, 17, and 19; a 2'-5'-ribonucleotide in position 7; and a C3Pi-C3OH moiety covalently attached at the 3'-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što smisleni lanac sadrži SEQ ID NO:98, a protusmisleni lanac sadrži SEQ ID NO:165; gdje smisleni lanac dodatno sadrži 2'-5'- ribonukleotide na položajima 15, 16, 17, 18, te 19; C3-OH 3' ostatak kovalentno vezan na 3'-kraju; i invertirani nebazni deoksiribonukleotidni ostatak kovalentno vezan na 5'-kraju; i gdje protusmisleni lanac dodatno sadrži 2'- O-metilom modificirane ribonukleotide na položajima 2, 4, 6, 8, 11, 13, 15, 17, te 19; 2'-5'-ribonukleotid na položaju 7; i C3Pi-C30H ostatak kovalentno vezan na 3'-kraju.
The lyophilised composition of claim 11 which, when reconstituted with 1.2 ml sterile water for injection, contains in each millilitre: 1.1 mg non-glycosylated des-atanyl-1, serine-125 human IL-2; 50 mg mannitol; 0.18 mg sodium dodecyl sulfate (SDS); 0.17 mg monobasic sodium phosphate; and 0.89 mg dibasic sodium phosphate to pH 7.5, wherein the IL-2 and SDS are in the form of aggregates such that the reconstituted composition has a specific turbidity (t) less than 1.1 cm2/g. 
Liofilizirani sastav prema patentnom zahtjevu 11, naznačen time, da kada je rekonstituiran s 1,2 ml sterilne vode za injektiranje, u svakom mililitru sadrži: 1,1 mg ne-glikoziliranog des-alanil-1, serin-125 humanog IL-2; 50 mg manitola; 0,18 mg natrijevog dodecil sulfata (SDS); 0,17 mg monobazičnog natrijevog fosfata; i 0,89 mg dibazičnog natrijevog fosfata do pH 7,5, kod čega su IL-2 i SDS u obliku agregata, tako da rekonstituirani sastav ima specifičnu zamućenost (7) manju od 1,1 cm?/g.
at least 90 mole percent terephthalic acid residues, based on the total amount of dicarboxylic acid residues in the one or more polyethylene terephthalate homopolymers or copolymers comprising 100 mole percent; 
(i) najmanje 90 molarnih postotaka ostataka tereftalne kiseline, prema ukupnoj količini ostataka dikarboksilnih kiselina u jednom ili više homopolimera ili kopolimera polietilen-tereftalata koji sadrže 100 molarnih postotaka; i
aqueous formulation is defined as the monohydrate of dihydrogenphosphate salt of formula I in 10 mM sodium acetate/0.8% saline solution at pH 4.5 ± 0.2. 
vodena formulacija je definirana kao monohidrat dihidrogenfosfatne soli formule I u 10 mM natrij acetata/0.8% slane otopine na pH 4.5 + 0.2.
Also suitable for use in the present invention are therapeutic conjugates of complexed 227Th with a peptide, amino acid, steroidal or non-steroidal hormone, folate, estrogen, testosterone, biotin, or other specific-binding compounds with molecular weight typically below 10 000 g/mol. 
skupinu za ciljanje tkiva odabranu od protutijela, konstrukata protutijela, fragmenata protutijela, 5 konstrukata fragmenata ili njihovih smjesa, peptida, aminokiseline, steroidnog ili nesteroidnog hormona, folata, estrogena, testosterona ili biotina, -
A pharmaceutical composition comprising a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein 
Farmaceutski sastav prikladan za oralnu primjenu koji sadrži spoj formule I:
By adopting a bow caster, the height of which is lower than in the vertical-type caster, the ferrostatic pressure at the inside of the solidifying slab is lower for the same cross-section area and speed from the continuous casting outlet, whereby the bulging effect can be avoided or reduced to a minimum. 
Prihvaćanjem odljeva oblika luka, čija je visina niža nego u ljevaču okomitog tipa, ferostatski tlak je u unutrašnjosti slaba, koji očvršćuje, niži za isto područje poprečnog presjeka i brzinc iz izlaza kontinuiranog lijevanja, pri čemu sc može izbjeći ispupčenje ili se ono može smanjiti na najmanju moguću mjeru..
The composition of claim 19, characterized in that it further comprises at least one anti-tumoral antibody. The composition of claim 19, characterized in that it further comprises at least one cytotoxic/cytostatic agent. 
Pripravak iz patentnog zahtjeva 14 ili 15, naznačen time da dalje sadrži najmanje jedno sredstvo kao kombinacijski produkt za istodobnu, odvojenu ili uzastopnu upotrebu, pri čemu rečeno sredstvo jest citotoksično/citostatko sredstvo.
An MMVF substrate according to any of claims 16 to 18, wherein the MMVF substrate has an ignition loss of up to 2 wt%, such as 0.5 to 2.0 wt%, preferably 0.8 to 1.5 wt%, and wherein the MMVF substrate has a density in the range of 60 kg/m3 to 150 kg/m3, preferably 80 to 130 kg/m3. 
MMVEF supstrat sukladno bilo kojem od zahtjeva 16 do 18, naznačen time, da MMVF supstrat ima gubitak izgaranja do 2 tež%, kao što je 0,5 do 2,0 tež%, poželjno 0,8 do 1,5 tež% 1 pri čemu MMVEF supstrat gustoće u rasponu od 60 kg/m3 do 150 kg/m3, poželjno od 80 do 130 kg/m3.
Preferably the elastomer material of the invention comprises a base thermoplastic elastomer compounded with a colourant to have the absorption coefficient for laser light of 0.5-2.5 mm−1. 
Poželjno je da navedeni elastomerni materijal sadržava osnovni termoplastični elastomer koji je pomiješan sa sredstvom za bojenje, da bi se dobio koeficijent apsorpcije za lasersko svijetlo od 0.5 -2.5 mm.
the compound of formula (XIII) is subjected to a saponification reaction in a basic medium in order to obtain the compound XVIII: 
spoj s formulom (XIII) se podvrgava reakciji saponifikacije u bazičnom mediju kako bi se dobio spoj (XVIII): [image]
The coupling according to claim 1, wherein said engagement means is constituted by a partial thread. 
Spoj prema zahtjevu 1, naznačen time što je sredstvo za zahvaćanje napravljeno kao djelomični navoj (2).
A compound of any one of claims 1 to 8 for use in therapy. 
Spoj bilo kojeg patentnog zahtjeva od 1 do 8 za primjenu pri liječenju. 11.
A method according to claim 3, wherein in the thermo-electric melting process the current supplied in the assembly (31) runs through the contact edges (23, 24) with an intensity such as to cause a raising of the temperature in the melting portions (21, 22), enough to melt said melting portions (21, 22). 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da u termoclektričnom procesu taljenja struja koja se isporučuje u sklopu (31) prolazi kroz kontaktne rubove (23, 24) s intenzitetom koji uzrokuje podizanje temperature u dijelovima za taljenje (21, 22), koje je dovoljno da se rastale navedeni dijelovi za taljenje (21, 22).
a first heat sink and a second heat sink arranged forward of and laterally shifted to opposing sides of the heat exchanger, each of the heat sinks configured to be in thermal contact with an operational heat emitting component of the vehicle; and a plurality of air deflectors configured to alter a flow of the ambient air through the thermal dissipation system by transitioning between two or more configurations, wherein in a first configuration the air deflectors are arranged to direct all the ambient air passing through the thermal dissipation system through one of the first and second heat sinks and then subsequently rejoin the ambient air after flowing through the heat exchanger and in a second configuration the air deflectors are arranged to allow a portion of the ambient air to flow directly to the heat exchanger by passing through a gap between the first heat sink and the second heat sink. 
prvi pasivni hladnjak (220) i drugi pasivni hladnjak (230) postavljene sprijeda i bočno pomaknute na suprotne strane izmjenjivača topline, svaki od pasivnih hladnjaka je konfiguriran da je u toplinskom kontaktu s radnom komponentom vozila koja emitira toplinu; i mnoštvo usmjerivača zraka (111, 121, 131) koji su konfigurirani da mijenjaju strujanje okolišnjeg zraka kroz sustav za toplinsku disipaciju prijelazom između dvije ili više konfiguracija, pri čemu su u prvoj konfiguraciji usmjerivači zraka postavljeni da usmjeravaju cjelokupni okolišni zrak koji prolazi kroz sustav za toplinsku disipaciju kroz jedan od prvog i drugog pasivnog hladnjaka i zatim se naknadno spajaju s okolišnjim zrakom nakon strujanja kroz izmjenjivač topline i u drugoj konfiguraciji usmjerivači zraka su raspoređeni da omogućavaju dijelu okolišnjeg zraka da struji izravno na izmjenjivač topline prolazom kroz razmak između prvog pasivnog hladnjaka i drugog pasivnog hladnjaka.
A pharmaceutical formulation comprising an anti-IL-17 antibody at a concentration in the range of about 80 mg/ml to about 150 mg/ml, citrate buffer at a concentration of about 20 mM, sodium chloride at a concentration of about 200 mM, polysorbate-80 at a concentration in the range of about 0.02% (w/v) to about 0.03% (w/v), and pH at about 5.7, wherein the anti-IL-17 antibody comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein LCVR comprises LCDR1, LCDR2, LCDR3, and HCVR comprises HCDR1, HCDR2, HCDR3, and wherein: 
Farmaceutska formulacija, naznačena time što sadrži protutijelo protiv IL-17 u rasponu koncentracija od 80 mg/ml do 150 mg/ml, citratni pufer u koncentraciji od 20 mM, natrijev klorid u koncentraciji od 200 mM, polisorbat-80 u rasponu koncentracija od 0,02% (tež./vol.) do 0,03% (tež./vol.), te pH od 5,7, gdje protutijelo protiv IL-17 sadrži protutijelo s lakim lancem (LC) i teškim lancem (HC), gdje navedeni LC ima aminokiselinski slijed sa SEQ ID NO: 4, a navedeni HC ima aminokiselinski slijed sa SEQ ID NO: 5.
A compound according to any one of claims 1 to 4 for use in treating an endoparasitic infection in a mammal. 
Paraziticidni sastav za uporabu prema zahtjevu 15, naznačen time, da se radi o endoparazitnim infekcijama koje
comprises a light chain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:87; 
(ii) obuhvaća slabi lanac koji ima najmanje 90% identiteta sekvence prema aminokiselinskoj sekvenci SEQ ID NO:87;
A method for preparing a polymorph form as defined in any one of claims 1 to 3, which comprises treating 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide with methanesulfonic acid at a temperature between 20-80°C. 
Postupak dobivanja polimorfnog oblika u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time što se sastoji u obradi 4-(4-metilpiperazin-1-ilmetil)-N-[4-metil-3-(4-piridin-3-iltiazol-2-ilamino)fenil]benzamida metansulfonskom kiselinom, na temperaturi između 20 i 80 °C.
Yet another embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of acute and chronic neuropathic pain. 
Uporaba prema zahtjevu 12, naznačena time da joj je svrha liječenje akutne i kronične neuropatske boli.
a concentrate of micellar casein, a milk protein concentrate, and 
koncentrat micelarnog kazeina, - > koncentrat mliječnog proteina, i -
is H, halogen, perhaloalkyl, CN, SR5, NHR5, N(R5)2, aryl, or heteroaryl, wherein said aryl can be optionally substituted with up to two substituents selected from C1-8 alkyl, halogen, perhalo alkyl, and alkoxy, and said heteroaryl can be optionally substituted with up to two substituents selected from halogen and C1-8 alkyl; 
je H, halogen, perhaloalkil, CN, SR5, NHR5, N(R5)2, aril ili heteroaril pri čemu je navedeni aril po izboru supstituiran sve do sa po dva supstituenda izabrana iz skupine koju čine C1-8alkil, halogen, perhalo alkil i alkoksi te je navedeni heteroaril po izboru supstituiran sve do sa po dva supstituenda izabrana iz skupine koju čine halogen i C1-8alkil;
The cellulose reactive glyoxalated copolymer composition according to claim 1, wherein the dry weight ratio of glyoxal:cationic copolymer ranges from about 10 to about 35 glyoxal to about 90 to about 65 cationic copolymer. 
Sastav glioksaliranog kopolimera reaktivnog sa celulozom prema zahtjevu I ili 2, gdje je suhi omjer masa glioksal: kationski kopolimer u rasponu od 10 do 35 glioksal prema 90 do 65 kationski kopolimer.
An oxycodone hydrochloride composition comprising (i) oxycodone hydrochloride, and (ii) 14-hydroxycodeinone at a level of less than 25 ppm. 
Postupak prema zahtjevu 1, naznačen time da sastav oksikodon hidroklorida ima razinu 14-hidroksikodeinona manju od 15 ppm.
The mouthpiece lining paper as claimed in claim 3, wherein a substance which has a matrix and substances with a sensory action enclosed therein in encapsulated form is applied to said surface areas that are located between said elevations. 
Papir za usnik kao što je navedeno u zahtjevu 4 ili zahtjevu 5, naznačeno time da je na površine (2) nanesena supstanca koja sadrži matricu i tvari sa senzornim učinkom u nju zatvorene u obliku kapsule.